Ascletis Reveals Promising Results for ASC30 in Weight Management Trials

Ascletis Unveils Positive Findings from Phase Ib Study of ASC30

Ascletis Pharma Inc., a biotechnology firm based in Hong Kong, has shared exciting topline results from its recent Phase Ib multiple ascending dose (MAD) study in the United States, exploring ASC30, a novel oral GLP-1 receptor (GLP-1R) agonist aimed at managing obesity. The findings indicate potential for ASC30 to be a significant player in the treatment of obesity, showcasing considerable weight reduction effects.

The Phase Ib study, categorized as double-blind and placebo-controlled, involved diverse dosing schemes and encompassed participants with a body mass index (BMI) between 30 and 40 kg/m². The investigation was conducted across three distinct weekly titration protocols, blending doses of 2 mg, 10 mg, 20 mg, and 40 mg along with different loading strategies. The results revealed that participants experienced an average body weight reduction of 6.5% when treated with ASC30 over four weeks, attributed to the two dosing schemes that used mid-range and gradual increase tactics. Notably, these reductions were superior compared to placebo, demonstrating strong efficacy in weight management.

In addition to weight loss, ASC30 exhibited a favorable safety profile. Side effects were primarily mild, focusing on gastrointestinal (GI) disturbances, and participants reported no instances of vomiting in one of the dosing groups. Such tolerability reinforces the promise of ASC30 as an adjustable treatment option, being well-received among various participants.

As the study progressed, researchers confirmed no significant adverse events, nor were any serious health complications reported, reinforcing the drug's safety. The consistent monitoring during the trial signified that participants were carefully observed with all vital signs, clinical tests, and ECGs showing normal results.

The Path Ahead for ASC30

Following the promising findings from the Phase Ib trial, an application to the FDA has been initiated for a 13-week Phase IIa study of ASC30. The new trial protocol is designed to leverage the